Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of SIR-Spheres Plus Sorafenib as First Line Treatment in Patients With Non-Resectable Primary Hepatocellular Carcinoma

NCT00712790 is registered in ClinicalTrials.gov with Singapore Clinical Research Institute as lead sponsor.

NCT NCT00712790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00712790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of SIR-Spheres Plus Sorafenib as First Line Treatment in Patients With Non-Resectable Primary Hepatocellular Carcinoma
Lead sponsor
Singapore Clinical Research Institute
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2008
Completion date
April 30, 2014
Enrollment
35 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma